Home > News > Recent cases

Recent cases

Accord Healthcare v Regents of the University of California [2024] EWHC 2524 (Pat)8 October 2024Justin Turner KC appeared for the Claimants and Andrew Lykiardopoulos KC appeared for the Defendants in this action to revoke the patent and invalidate the SPC owned by the First Defendant and exclusively licensed to the Second Defendant. The patent in suit, EP 196, claimed the compound enzalutamide for the treatment of hormone refractory prostate […]
Pfizer v Glaxosmithkline Biologicals [2024] EWHC 2523 (Pat) 7 October 2024Tom Moody-Stuart KC appeared for the Claimant (Pfizer) and Dr Justin Turner KC appeared for the Defendant (GSK) in an action concerning vaccines for respiratory syncytial virus (RSV). The proceedings concerned two GSK patents – EP 258 and EP 710. Both of these related to a vaccine for RSV. Pfizer brought these proceedings in an […]
Motorola Mobility v Ericsson [2024] EWCA Civ 110030 September 2024Michael Tappin KC appeared for the successful defendants (“Ericsson”) on an appeal by the claimants (“Lenovo”) against an order dismissing its application for an interim injunction to restrain Ericsson from doing acts which Lenovo alleged infringed one of its standard-essential patents (“SEPs”) until final judgment in the claim. Lenovo’s application arose out of a wider […]
Lunak Heavy Industries v Tyburn Film Productions [2024] EWHC 2312 (Ch)9 September 2024Jonathan Hill appeared for the Appellants (“Lunak” and “Lucasfilm”), and Tom Moody-Stuart KC and Joshua Marshall appeared for the Respondent (“Tyburn”) in this appeal against the order of Master Kaye (“the Master”) by which she rejected the Appellants’ application for the claim made against them in unjust enrichment to be summarily dismissed or alternatively struck […]
Cloud Cycle v Verifi [2024] EWHC 2001 (Ch)6 August 2024James Abrahams KC and Edmund Eustace appeared for the Defendants (“Verifi”) in a patent dispute relating to the Claimant’s (“Cloud Cycle’s”) system for monitoring a property of concrete (known as ‘slump’) in a mixing truck, and its alleged infringement of one of Verifi’s patents (“EP689”). Unusually, the validity of EP689 was not in issue, and […]
R2 Semiconductor v Intel [2024] EWHC 1974 (Pat)31 July 2024Andrew Lykiardopoulos KC appeared for the defendants (“Intel”) and Edmund Eustace appeared as junior counsel for the claimant (“R2”) in proceedings concerning a dispute on infringement and validity of an R2 patent for semiconductor technology (“the Patent”). The Patent claimed a form of circuitry for a voltage regulator, which R2 alleged was infringed by processors […]
Panasonic v Xiaomi [2024] EWHC 1733 (Pat)5 July 2024Isabel Jamal appeared as junior counsel for the Claimant (“Panasonic”) in an application for declaratory relief made by the First to Fourth Defendants (“Xiaomi”) in ongoing FRAND proceedings. Xiaomi sought declarations that Panasonic’s FRAND commitment required it to offer Xiaomi an interim licence to various of Panasonic’s patents declared essential to the 3G and 4G […]
Engineer.AI Global v Appy Pie [2024] EWHC 1430 (IPEC)19 June 2024Engineer.AI Global Ltd provided “no code” app development services. It had a series of registered trade marks including BUILDER and BUILDER.AI in word and in stylised forms. The second defendant Appy Pie LLP supplies “no code” app builders of the drag and drop type. In 2022, Engineer.AI sued the defendants for infringement in respect of […]
easyGroup v Beauty Perfectionists [2024] EWHC 1441 (Ch)13 June 2024James Abrahams KC and Maxwell Keay represented the successful defendants (“Beauty Perfectionists”) in trade mark infringement proceedings brought by the claimant (“easyGroup”), regarding Beauty Perfectionists’ use of versions of the sign “easyCOSMETIC” in relation to its online cosmetics business. easyGroup relied on two marks for the word “EASYJET”, registered for various goods and services including, […]
Samsung v Alexion [2024] EWHC 1407 (Pat)6 June 2024James Whyte appeared for the claimant (“Samsung”) in its successful application to expedite a trial, in which Samsung seeks to revoke a patent owned by the defendant (“Alexion”). The patent, which was granted earlier this year, is said to give Alexion refreshed rights over the antibody drug eculizumab. Eculizumab is an orphan drug which is […]